Management and prognosis in patients with ST- elevation myocardial infarction: from single - center study

Bo ZHANG,Rong-chong HUANG,Da YIN,Yan ZHANG,Hao ZHU,Jun LIU,Xu-chen ZHOU

2011-01-01

Abstract:[Objective] To analyze current clinical practice and outcome and prognosis of patients with ST-segment elevation myocardial infarction (STEMI). [Methods] This was a prospective and simple-center observation study. All the 174 patients with acute STEMI admitted to the hospitals from June 1st 2009 to June 1st 2010 were included. Same questionnaire and criteria were used. The patients were followed-up for 6 months after they were discharged from the hospital. [Results] The average age of patients was (64.3 ± 14.1) years older. Some patients, 38.5% of the all recognized the disease as heart disease. The median symptom-to-door time was 105 minutes. The proportion of selecting emergency reperfusion therapy was 63.2%. The median door-to-needle time was 130 minutes. The median door-to-balloon time was 145 minutes. In-hospital treatment included aspirin, 99.4%; clopidogrel, 98.9%; statins, 97.7%; low molecular weight heparin, 99.4%; β-blocker, 78.2%; angiotensin converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB), 70.1%. The in-hospital mortality was 9.8%, and the mortality in females was obviously higher than that in males (20.9% vs 6.3%, P = 0.005). The mortality in older patients (≥65 years old) was obviously higher than that in younger patients (18.3% vs 0%, P < 0.001). Follow-up treatment were aspirin, 92.9%; clopidogrel, 60.3%; statins, 82.1%; β-blocker, 67.3%; ACEI/ARB5, 2.6%. The follow-up mortality was 3.8%. Multivariate regression analysis showed that age was an independent risk factor of death in STEMI patients during hospitalization. [Conclusions] Longer pre-hospital delay is commonly seen in STEMI patients. There is still certain gap between emergency reperfusion therapy, the evidence-based medicine agent application after discharge and related guidelines.